Stock Events

Stock Events

Panbela Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
-1.22
-0.89
-0.56
-0.22
Expected EPS
-1.2216680000000002
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-23.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow X70.MU. It's not an investment recommendation.
Tesla
4
TSLA
Alphabet
3
GOOG
Bitcoin
3
BTC.CRYPTO
Ethereum
3
ETH.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that competes in the development of treatments for cancer, a key focus area for Panbela Therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm focusing on human therapeutics, including cancer treatments which puts it in direct competition with Panbela Therapeutics in the oncology sector.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is known for its strong portfolio in oncology, directly competing with Panbela Therapeutics in the cancer treatment market.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer drugs among other areas, making it a competitor to Panbela Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company with a broad range of drugs, including cancer treatments that compete with Panbela Therapeutics' offerings.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with its extensive research and development in oncology, competes with Panbela Therapeutics in the cancer drug market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in the pharmaceutical and diagnostics world, with a significant focus on oncology, competing with Panbela Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong presence in the oncology sector, developing treatments that compete with Panbela Therapeutics' cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for serious medical conditions, including cancer, making it a competitor.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer treatments, competing with Panbela Therapeutics.

About

PANBELA THERAPEUTICS INC
Show more...
CEO
Jennifer K. Simpson
Employees
8
Country
United States
ISIN
US69833W2061

Listings

STU
DE
X70.STU
MU
DE
X70.MU
OTC Link
US
PBLA

0 Comments

Share your thoughts

FAQ

What is Panbela Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Panbela Therapeutics stocks are traded under the ticker X70.MU.
What is Panbela Therapeutics revenue for the last year?▼
Panbela Therapeutics revenue for the last year amounts to 0 EUR.
What is Panbela Therapeutics net income for the last year?▼
X70.MU net income for the last year is -23.31M EUR.
How many employees does Panbela Therapeutics have?▼
As of September 04, 2026, the company has 8 employees.
In which sector is Panbela Therapeutics located?▼
Panbela Therapeutics operates in the Health & Wellness sector.
When did Panbela Therapeutics complete a stock split?▼
The last stock split for Panbela Therapeutics was on June 01, 2023 with a ratio of 1:30.
Where is Panbela Therapeutics headquartered?▼
Panbela Therapeutics is headquartered in Waconia, United States.